Translatum Medicus

Translatum Medicus Overview

  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 2

Translatum Medicus General Information

Description

Operator of a preclinical drug development company intended to focus on macrophage modulation to treat dry AMD and other blinding eye disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 661 University Avenue
  • 1336-Suite 1300
  • Toronto, Ontario M5G 0B7
  • Canada
+1 (647) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Translatum Medicus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 11-May-2016 Completed Generating Revenue
1. Grant 01-Apr-2016 000.00 Completed Generating Revenue

Translatum Medicus Executive Team (2)

Name Title Board Seat Contact Info
Shelley Boyd MD Founding President & Chief Scientific Officer
Kenneth Howling Chief Financial Officer

Translatum Medicus Investors (2)

To view Translatum Medicus‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator 000 0000 000000 0
Ontario Bioscience Innovation Organization Not-For-Profit Venture Capital 000 0000 000000 0

Ready to get started?

Request a free trial